NCT03641755View on ClinicalTrials.gov

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

April 27, 2022

Study Completion Date

October 22, 2025

Conditions
Breast Cancer
Interventions
DRUG

Sapacitabine

Sapacitabine may help to stop the growth of some types of cancers

DRUG

Olaparib

Olaparib is an inhibitor of PARP (poly \[adenosine diphosphate-ribose\] polymerase), which means that it stops PARP from working

Trial Locations (2)

02215

Dana Farber Cancer Institute, Boston

02142

Broad Institute of MIT, Cambridge

Sponsors
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER